Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news...

On 7/14/10, Endocrine / Metabolic Drugs and Drug Safety / Risk Management FDA Advisory Panels voted 20-12 to keep Glaxo's (NYSE:GSK) diabetes drug AVANDIA on the market, following a two-day joint meeting held to review potential cardiovascular safety concerns such as heart attacks.

On 7/14/10, Peregrine Pharma (NASDAQ:PPHM) initiated an un-blinded study for bavituximab (monoclonal antibody that targets cell membrane component phosphatidyl-serine or PS) in the front-line treatment of non-small cell lung cancer (NSCLC) in combo with carboplatin and paclitaxel and expects to complete patient enrollment by mid-2011 while a second double-blinded study for refractory NSCLC has expected top-line data by year-end 2011.

Below are summaries of the most recent articles written by Mark Messier at www.BioRunUp.com - please visit the site to read the full articles, in addition to many other free tools and strategies related to binary event investing.

Vivus (NASDAQ:VVUS) Vote on the Results of Qnexa's FDA Panel

Posted: Thu, 15 Jul 2010 02:23:34 +0000

Yes = Majority of positive votes No = Majority of negative votes This poll closes 7/15/10 at 3:30pm PST

Next on the Run-Up List: JAZZ and MELA

Posted: Thu, 15 Jul 2010 00:45:32 +0000

Now that I have closed my run-up position VVUS it is time to move on to the next play. Fortunately we have two more FDA Advisory Panels nicely timed for entry into a run-up. What are those? JAZZ and MELA Below I will post a brief summary of each company with a link to their articles. [...]

BioRunUp.com is Now Partnered with MikeHavRX.com

Posted: Tue, 13 Jul 2010 20:04:35 +0000

We are happy to announce that BioRunUp.com is now partnered up with MikeHavRX.com What does this mean for BioRunUp.com subscribers?  [...]

Introducing BioRunUp Forums

Posted: Mon, 12 Jul 2010 19:30:29 +0000

I received an overwhelmingly positive reponse a few weeks ago when I posted the question "Would You Use a Biotech Trading Forum on BioRunUp.com?".  I have been hard at work developing and organizing the forum (with generous assistance from MrGroove at GroovyPost.com) , and I am happy to announce the release of the BioRunUp Users [...]

www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and pending binary events such as FDA decisions and clinical trials. The HavRx Regulatory Catalyst Index update report is currently tracking 598 entries and 402 companies (with approximately 200 stocks trading under $5 per share and 63 private companies). This subscriber overview article includes an email archive web link for a 50% discount ($150) promo code off the regular one-year, non-recurring subscription price... http://www.mikehavrx.com/articles/20100714_1

Disclosure: No positions